Posted by Michael Wonder on 15 Aug 2022
MHRA authorises Moderna's Omicron containing bivalent booster in the UK
15 August 2022 - Study results show mRNA-1273.214 has demonstrated significantly higher antibody titres against Omicron BA.1 and BA.4/5 sub-variants when compared with mRNA-1273.
Moderna today announced that the MHRA in the UK has granted conditional authorisation for the use of the Omicron containing bivalent COVID-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron) as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern (BA.1).
